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Abstract 
Read-across as an alternative assessment method for chemical toxicity has growing interest in both the 
regulatory and industrial communities. The pivotal means of acquiring acceptance of a read-across 
prediction is identifying and assessing uncertainties associated with it. This study has identified and 
summarised in a structured way the variety of uncertainties that potentially impact acceptance of a read-
across argument. The main sources of uncertainty were established and divided into four main categories: 
i) the regulatory use of the prediction, ii) the data for the apical endpoint being assessed, iii) the read-
across argumentation, and iv) the similarity justification. Specifically, the context of, and relevance to, the 
regulatory use of a read-across will dictate the acceptable level of uncertainties. The apical endpoint (or 
other) data must be of sufficient quality and relevance for data gap filling. Read-Across argumentation 
uncertainties include: 1) mechanistic plausibility (i.e., the knowledge of the chemical and biological 
mechanisms leading to toxicity), 2) completeness of the supporting evidence, 3) robustness of the 
supporting data, and 4) Weight-of-Evidence. In addition, similarity arguments for chemistry, physico-
chemical properties, toxicokinetics and toxicodynamics are linked to these read-across argumentation 
issues. To further progress in this area, a series of questions are proposed with the goal of addressing each 
type of uncertainty. 
 
Keywords: read-across, toxicity, sources of uncertainty, types of uncertainty, guiding questions 
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Highlights: 
 Six read-across case studies were reviewed to establish overarching uncertainties. 
 Twelve types of uncertainties identified for read-across for toxicity prediction. 
 Questions were formulated to assist in assessing uncertainties in read-across. 
 Comparison with existing schemes for read-across uncertainty is given. 
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Introduction 
 
Toxicologically data-poor substances dominate the universe of industrial chemicals. The paucity of data 
and information has motivated the use of chemical grouping and read-across as a data gap filling 
technique [1]. However, whilst it is a commonly applied technique, among stakeholders using it there is 
agreement that for better regulatory acceptance of read-across more experience is needed on how 
confidence in the prediction could be enhanced i.e., how to lower uncertainties [2-5]. In order to achieve 
this goal, for regulatory application at least, the Organisation for Economic Co-operation and 
Development (OECD) has developed technical guidance describing a workflow to identify analogues, or 
form categories, of similar chemical structure to allow for read-across predictions to be made to fill 
toxicological data gaps [1]. In a related activity, in 2015 the OECD launched the Integrated Approach to 
Testing and Assessment (IATA) Case Studies Project under its revised Cooperative Chemicals Assessment 
Programme. The aim of this project was to increase experience of the use of IATA by developing case 
studies which, in turn, could help inform the better use of read-across and hence development of 
guidance. The case studies developed were intended to be examples of read-across predictions that would 
be fit for regulatory use. Individual case studies submitted from member countries and other 
organisations were reviewed within the IATA Case Studies Project. The review process concentrated on 
the: 1) the strongest aspects of case study, 2) the areas of uncertainty within the case study, 3) the 
identification of, and agreement for, areas of further development of guidance, and 4) the possibility of 
the use of the case study in various regulatory contexts. 
The IATA Case Studies Project enabled the OECD to take a more reflective and dynamic analysis of the 
application of read-across for toxicological data gap filling than would otherwise have been possible [1, 4, 
6]. Specifically, the analysis focused on establishing consistency in the information required to 
demonstrate: 1) how to document the justification for a read-across, 2) how to perform read-across for 
more complex endpoints (e.g., repeated dose toxicity), 3) how to develop and gain support for 
quantitative read-across which may be applicable for hazard characterisation, 4) how to take mechanistic 
considerations into account in grouping chemicals, 5) how to derive weight-of-evidence (WoE) 
conclusions based on the results from alternative methods (and New Approach Methodologies (NAMs)), 
and 6) how to assess the uncertainty associated with the read-across. 
Additional to the on-going activities described above there have been other recent efforts to address the 
issues raised by the OECD within academia, government and industries. These efforts began the process 
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of the refinement and improvement of how read-across is documented and concentrated on clarifying 
the seminal issues and overcoming the challenges posed by the OECD (see Patlewicz et al. [7, 8] and 
Schultz and Cronin [9]). Several different frameworks for undertaking read-across are available, as 
described in both regulatory technical guidance and peer-reviewed scientific literature [6, 10-16]. Such 
guidance includes two multi-step procedures, one for the analogue- and one for the category-approach 
that includes several key features. Patlewicz and co-workers [7, 8] note that the OECD framework is an 
endpoint specific, bottom-up approach that is a generalisation of the ECHA approach. These frameworks 
have recently been summarised and a more generic framework proposed [8]. 
A consistent issue among these frameworks is that of defining and, where possible, quantifying the 
different elements and overall uncertainty within a read-across hypothesis, justification and prediction. 
Specifically, given the challenges of gaining regulatory acceptance of read-across-based predictions, there 
have been efforts to explore how read-across justifications can be evaluated critically so that uncertainties 
can be explicitly identified and practical strategies can be brought to bear on reducing those uncertainties 
[6, 10-15]. The criteria covered by five key publications [6, 10, 12, 13, 15] are summarised in Tables S1-S5 
in the Supplementary Information. High confidence (i.e., low concerns about potential error in the 
prediction) is linked to a read-across argument where there is information and data showing why the 
prediction is valid. To some extent at least, the development by the European Chemicals Agency (ECHA) 
of the Read-Across Assessment Framework (RAAF) was a further attempt to facilitate regulatory 
acceptance. The RAAF provides a means to assess (quantitatively) the documentation and evidence of a 
number of read-across scenarios, however it does not provide a comprehensive review of the 
uncertainties associated with read-across [15].  
The purpose of this investigation was to review the issues of uncertainty as related to read-across for a 
complex health endpoint with the specific objective of using this knowledge to assist in the development 
of guidance on assessing uncertainty in read-across for supporting regulatory decisions, e.g. (quantitative) 
risk assessment, classification and labelling, screening and prioritisation etc. The overall aim was to report 
all sources and types of uncertainty previously identified in case studies that may affect the overall 
uncertainty. Further, for each type of uncertainty a series of questions was proposed which were intended 
to practically assist both the developer and user in assessing the uncertainty surrounding a read-across 
prediction. 
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Selection and Analysis of Read-Across Case Studies 
 
Selection of Case Studies  
The intention of selecting read-across case studies was not to be all inclusive but rather to examine studies 
where the hypothesis and justification for grouping has a similar level of complexity. The regulatory 
context of each case study was developing a point of departure suitable for quantitative risk assessment, 
although the uncertainties were developed in terms of being usable for other regulatory contexts. Among 
the criteria used in selecting the case studies reviewed in this investigation was that the OECD “Template 
for IATA Case Studies on Read-Across” [5, 6] or a highly similar template for documenting the read-across 
prediction was available and had been utilised to guide the analysis. The case studies were selected such 
that appropriate information was available from the (OECD or other) template relating to: 
1) the purpose of the read-across, 
2) the hypothesis for the analogue approach/category, 
3) details of the source chemicals/category members, 
4) justification of data gap filling, and 
5) the strategy for, and integrated conclusion of, data gap filling. 
The last factor was particularly important with regard to the assessment of uncertainties. 
Four other criteria were also included in the evaluation process: that the data gap was for a complex 
toxicological endpoint, in this case repeated-dose toxicity; the case studies considered were comparable 
in terms of their purpose and how they were undertaken; the category approach was applied; and that 
different read-across hypotheses were considered (e.g., based on different modes of action and/or 
different toxicokinetics) to cover a wide range of possible scenarios of chemical similarity for read-across.  
 
Case Studies Considered 
Following the selection process, six read-across case studies were identified that met the selection criteria 
– it is recognised that this was not an exhaustive list and there is a bias to those arising from the OECD 
IATA programme [14, 17-19] and the authors’ own work [20, 21]. However, these case studies are 
representative of the current state of the art and focus on chemical group-based read-across with an array 
of chemicals with data gaps (i.e., target chemicals). Inevitably, the case studies differ in the number of 
chemicals with data (i.e., the source substances), which varies from one to several as well as (as defined 
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by the selection criteria) the read-across hypothesis. The six read-across case studies (CSs) considered 
were all for repeated dose toxicity and are summarised in Table 1.  
Table 1. Summary of the six read-across case studies for repeated dose toxicity evaluated as part of the 
identification, evaluation and assessment of sources and types of uncertainties.   
Case Study 
(CS) 
Number 
Compounds 
Considered 
Read-Across Hypothesis and The Proposed 
Mechanism of Action Exhibited by the 
Compounds 
Reference 
CS1 n-Alkanols Basal cytotoxicity / non-polar narcosis Mode-of-
Action (MoA) with no systemic toxicity and high 
No Observed Effects Levels (NOEL) linked to 
Phase 1 oxidative metabolism to CO2 
OECD [17] 
CS2 2-Alkyl-1-alkanols Basal cytotoxicity / non-polar narcosis MoA 
with no systemic toxicity and moderate NOEL 
values linked to Phase 2 glucuronidate 
metabolism 
OECD [18] 
CS3 Aryl alcohol alkyl 
carboxylic esters 
Basal cytotoxicity / non-polar narcosis MoA 
with no systemic toxicity and moderate NOEL 
linked to ester hydrolysis 
OECD [19] 
CS4 Short-chain 
mono-
alkylphenols 
Polar narcosis MoA with no systemic toxicity 
and moderate NOEL values linked to Phase 2 
glucuronidate metabolism 
Mellor et al. 
[21] 
CS5 Allyl esters An electrophilic MoA with systemic toxicity (i.e., 
liver fibrosis) and low NOEL values. The 
justification was that ester hydrolysis leads to a 
common metabolite, allyl alcohol, which was 
metabolised to the same definitive toxicant - 
acrolein 
OECD [14] 
CS6 β-Olefinic 
alcohols 
An electrophilic MoA with systemic toxicity 
(liver fibrosis) and low NOEL values linked to 
oxidative metabolism of the parent alcohol 
leading to a different definitive electrophilic 
Przybylak et al. 
[20] 
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toxicant, exhibiting the same reactive 
mechanism - Michael Addition 
 
Analysis of the Selected Read-Across Case Studies Focussing on Uncertainty 
The uncertainty of each read-across case study was analysed with regard to the fifth topic of the OECD 
Template [6], namely the consideration of “the strategy for and integrated conclusion of data gap filling”. 
This section is of two interrelated parts which firstly discusses the uncertainty associated with each part 
of the read-across and secondly makes an integrated conclusion which draws together all aspects of the 
read-across to assess its validity or potential fitness of purpose. Specifically for this analysis, the integrated 
conclusion was the focus of the analysis of the determination of uncertainties. 
 
Results and Discussion 
 
This study has assessed six read-across case studies for the prediction of repeated dose effects. The read-
across exercises have all been recorded on standardised templates which has allowed for an assessment 
of their relative uncertainties. It is important to note that this exercise was not intended as a retrospective 
exercise to evaluate, or otherwise, the quality or robustness of the read-across case studies, but to identify 
and compile a comprehensive list of uncertainties associated with read-across as a means to stimulate 
the creation of guidance. 
An examination of the six case studies revealed that all six studies addressed, to some extent at least, the 
overarching question - is the uncertainty acceptable to use the read-across prediction(s) to fill the data 
gap? All six case studies related to reading across a NOEL value; this is considered to be one of the most 
challenging applications of read-across and that uncertainties identified in this analysis could be applied 
broadly to other endpoints and uses. The answer to the question of whether the uncertainties are 
acceptable is on one hand part of the risk management decision or dictated by the relevant chemical 
legislation or required purpose. On the other, practical, hand, to address this question, different sources 
of uncertainty were identified and a variety of types of uncertainty described. Four main sources of 
uncertainty were identified and are listed in Table 2.  
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Table 2. Summary of the main overarching sources of uncertainty identified in the read-across case 
studies. 
Main Sources of Uncertainty in Read-Across 
I. Uncertainty related to the regulatory use (i.e., the impact the regulatory scenario will 
place on acceptable levels of uncertainty. 
II. Uncertainty related to the data for the endpoint under consideration for the source 
compound(s). 
III. Uncertainty related to the argumentation of the read-across including, but not limited 
to, data quality. This can be sub-divided into the following types: 
 
a) The approach taken to read-across, i.e. the type of similarity and grouping 
applied 
b) The mechanistic plausibility of the read-across argument  
c) The completeness of the argument provided to support the read-across 
d) The robustness of the argument from the hypothesis to execution of the read-
across 
e) The Weight-of-Evidence presented  
IV. Uncertainty related to the justification of similarity between the target and source 
compounds. This can be sub-divided into the following types: 
a) Definition and demonstration of similarity in chemical structure between the 
target and source compounds 
b) Definition and demonstration of similarity in physico-chemical properties 
between the target and source compounds 
c) Definition and demonstration of similarity in toxicodynamics including species 
and assay differences between the target and source compounds  
d) Definition and demonstration of similarity in toxicokinetics, focussed on 
Absorption, Distribution, Metabolism and Excretion (ADME) properties 
between the target and source compounds 
 
Based on our review, we recognised the sources of uncertainty are associated with types (or elements) of 
uncertainty (Table 3). While not all the case studies identified or addressed all the types of uncertainty, 
and in some case studies they were even combined, Table 3 reports all the uncertainties found one or 
more times in our review. The sources and their interrelationships with types of uncertainty are 
summarised schematically in Figure 1.  
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INSERT FIGURE 1 HERE  
 
 
12 
 
 
Table 3. Definition of types of uncertainties identified in the read-across case studies. 
 
Number Individual 
Uncertainties in Read-
Across  
Description and Relevance  Source of 
Uncertainty – 
Numbered as 
per Table 2 
1 The context of, and 
relevance to, the regulatory 
use of the read-across 
prediction as defined by 
appropriate problem 
formulation. 
Regulatory use is usually defined at the start of the read-across but may also be applied at the 
end. The use defines the level of uncertainty that may be acceptable. Acceptable uncertainty is 
lower for risk assessment than for prioritisation and screening, respectively. Especially for risk 
assessment, the acceptable level of uncertainty may not be reached for all members of a 
category. The read-across must be relevant to the endpoint and question to be addressed. 
I 
2 Type of category / group 
including the definition of 
the applicability domain 
The number of target and source chemicals (i.e., the size of the applicability domain), impacts on 
uncertainty [13, 15]. Uncertainty increases, and is more difficult to assess, in the following order 
of scenarios: 
1) Many source substances to one target chemical, 
2) One source substance to one target chemical, 
3) Many source substances to many target chemicals, 
4) One source substance to many target chemicals. 
Uncertainty in a read-across prediction is defined by the extent of the interpretability and 
defensibility of the applicability domain which is described in a transparent manner. Whilst 
interpretability often decreases in going from one to many target chemicals, defensibility is 
typically increased. The applicability domain would normally be described in terms of the 
structural features and properties of the category.  
IIIa, IVa 
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3 The premise or hypothesis 
of the read-across 
A well-stated premise or hypothesis, described in a testable format is essential to assessing 
uncertainty in read-across. The hypothesis of the read-across is typically linked to other 
uncertainties. Uncertainty associated with the hypothesis of the read-across often (but not 
always) centred on the identification of the correct MoA (e.g., confirmation of the molecular 
initiating event and/or key events along an adverse outcome pathway). The hypothesis typically 
includes statements about uncertainties 4-11 in this Table. Overall, the premise or hypothesis 
must be relevant to the endpoint and use scenario.  
IIIa, IIId 
4 Mechanistic plausibility 
including completeness of 
the understanding of the 
MoA or AOP 
Mechanistic plausibility is a key element of defining and justifying the read-across hypothesis 
(Uncertainty 3). Assessment of the uncertainty of the mechanistic plausibility is based largely on 
the knowledge of the chemical and biological mechanism(s) resulting in the toxicity. Mechanistic 
assessments take account of the strength, consistency, and selectivity of the experimental 
evidence association with sets of data/information typically taken from a MoA. Strength is 
related to the number of intermediate or key events tested and the number of analogues tested 
within an assay or key event of an AOP – as well as how complete the AOP is. Consistency is 
related to data uniformity within a key event/mechanistic test and data regularity between 
different tests. Selectivity is related to the ability to discriminate between known positive (i.e., 
category members) and known negative (i.e., substances known to be outside the domain of the 
read-across). 
IIIb 
5 Similarity in chemistry The uncertainty in chemical similarity/dissimilarity is a key element of assessing the robustness 
of a read-across prediction. The underlying philosophy of read-across is that substances which 
are similar in chemical structure will have similar chemical properties and thereby, similar 
toxicological properties [13] (it is recognised that biological similarity may also be used as a 
means to justify a read-across). Thus, demonstrating similarities in chemistry is essential and 
becomes the starting point in any similarity argument unless there is clear evidence that 
similarity can be defined in terms of biology (e.g., similarity in an omics profile). Assessing 
similarity in chemistry is typically undertaken by examining structural information and relevant 
physico-chemical properties. This implies that, where practically possible, the chemical identity 
of target and sources chemicals are correct and stated explicitly (noting potential issues with 
mixtures and chemical substances of Unknown or Variable Composition, Complex Reaction 
IVa, IV4b 
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Products and Biological Materials (UVCB Substances)). The number and type of factors relating to 
chemical similarity must be relevant to the endpoint under consideration and will themselves 
affect the quality of the read-across [22, 23]. 
In using the analogue approach, i.e. a one-to-one read-across, establishing similarity in chemistry 
may be sufficient to establish the similarity justification to meet acceptable uncertainty. It is also 
often important to show that dissimilarities in chemistry are not toxicologically relevant. 
6 Toxicodynamic similarity Similarity in toxicodynamics is inter-related to several uncertainties in this table (notably 
Uncertainty 4). However, its separate assessment with regard to uncertainty may include 
information from studies with different species (e.g., rat, mouse or rabbit), different exposure 
durations (e.g., 45 to 54-day, 90-day and 2-year) and different exposure schemes (e.g., gavage, 
feed or drink, as well as dermal). 
IVc 
7 Toxicokinetic similarity Similarity in toxicokinetics, especially ADME properties, is seen as crucial to assessing 
uncertainty. Metabolism is often seen as the most contentious aspect of the toxicokinetic 
similarity justification. Specifically, when the hypothesis proposes that a metabolite induces the 
apical endpoint, the metabolic pathways and effects induced by metabolites need to be 
considered. In addition, similarity or a predictable trend in the rate of transformation has also to 
be considered. There are seldom experimental ADME data for all the target materials. 
Experimental metabolism data for one or more of the source substances are, however, critical to 
gaining acceptable uncertainty. Furthermore, it is critical to gaining acceptable uncertainty to 
have highly similar metabolic simulations of the target material(s) and source analogue(s). 
IVd 
8 The quality of the apical 
endpoint data used to fill 
the data gap   
The quality of the in vivo apical endpoint data read across provides one of the fundamental 
source of uncertainty in a read-across. Data with low uncertainty are sought, which may include 
aspects of the reliability of the data and relevance to the endpoint and context, as well as for 
human health / environmental effects. For example, in the context of the case studies considered 
in this investigation and repeated-dose toxicity in particular, low uncertainty can be considered 
to be associated with (amongst other possibilities) high quality in vivo data derived from GLP 
studies following an OECD test guideline (e.g., TG 408, 90-day Subchronic Oral Toxicity). For a 
II 
15 
 
GLP study the manner (e.g., reliability accuracy, precision, repeatability and reproducibility) by 
which the apical in vivo data are generated should be well documented.  
 
For data from a non-standard protocol or non-guideline studies, or performed according to 
outdated protocols, which may be used to support a read-across, expert judgment is required. A 
decision must be made as to whether the data can be used reliably without restrictions, the data 
can be used but with restrictions (e.g., Weight of Evidence) or the data are not usable (e.g., 
flawed experimental design, lack of understanding what the results mean, etc.). The decision on 
non-standardised data will also determine if the read-across is sufficient to meet the regulatory 
purpose. 
9 The consistency in the 
effects and severity of the 
apical in vivo hazard and 
their concordance with 
regards to the intermediate 
and apical effects and 
potency data 
If there is more than one source substance, the consistency or inconsistency in the outcomes and 
severity of the apical in vivo hazard affects uncertainty. Low uncertainty is associated with 
consistent phenotypic expression and consistent potency of the hazard among the source 
substances. Conversely, higher uncertainty is associated with inconsistent phenotypic expression 
and/or varied potency of the hazard among the source substances. Again, for the example of 
repeated-dose toxicity, it is not only crucial to have similar NOEL values but also having similar 
LOEL effects based on the same effects. A distinction is not made between adverse and non-
adverse effects. For other endpoints, communality in effects would be sought. 
Concordance with regards to the intermediate and apical effects and potency data has been 
described by Blackburn and Stuard [12], Schultz et al. [13] and OECD [6], (see Tables S2, S3 and 
S5 in the Supplementary Information, respectively). A complete data matrix and significant dose-
response relationships are required to assess concordance and determine uncertainty. 
II, IIIc 
10 Strength or robustness of 
the supporting data sets 
The type, quality and robustness of the supporting data sets provide an important means of 
reducing uncertainty. Supportive data are typically relevant in silico, in chemico and in vitro data 
and may also include other (relevant and acceptable) non-standard in vivo data. When data 
consistency is observed across the category, uncertainty is reduced. 
IIIc, IIId 
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11 The Weight-of-Evidence 
(WoE) supporting the 
prediction 
The WoE supporting the read-across prediction is garnered from all the information and data 
used in the read-across. The most important means of reducing uncertainty associated with the 
WoE was to supplement the read-across with relevant data from additional, possibly targeted, 
studies using alternative methods. Having consistency across the applicability domain for 
information from alternative methods is important to reduce uncertainty associated with the 
overall WoE. 
IIIc, IIId, IIIe  
12 Documentation and written 
evidence provided 
Uncertainty is reduced when the evidence is presented clearly and unambiguously including 
cogent descriptions, arguments and justifications. The evidence should relate the uncertainty in 
the read-across to that deemed to be acceptable and demonstrate that the level of uncertainty is 
acceptable for the stated purpose.  
Applicable to all 
sources and IIIa, IIIb, 
IIIc in particular 
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In general, examination of the six case studies that formed the basis of this investigation showed that 
confidence in a read-across prediction can be enhanced by providing mechanistic transparency and using 
appropriate experimental data from structural analogues. In addition, confidence is enhanced by using 
appropriate toxicokinetic properties in the form of absorption, distribution, metabolism and excretion 
(ADME) information, as well as, relevant in vitro, in chemico data, structure-activity relationships (SARs), 
and high throughput screening (HTS) information, especially as a means of substantiating chemical and 
biological similarity and increased WoE [9].  
Specific analysis of a series of 30 questions that are proposed (in Table 4) to address the 12 uncertainties 
listed in Table 3 was performed. Each case study was evaluated according to the questions in Table 4 
based on the information provided in the source document with regard to the assessment of 
uncertainties. The findings for each case study are presented in the Supplementary Information Table S6-
S11 and are summarised in Table 4. Table 4 confirms that increased uncertainty was often associated with 
the plausibility of the mechanism of action, toxicokinetics as well as the quality and relevance of the data. 
These are well established areas of concern (cf [9]) and indicate where future effort is required. Analysis 
of a read-across prediction using the questions in Table 4 proved to be a rapid and efficient means of 
determining and analysing the uncertainty(ies). The questions are practical and pragmatic and cover all 
aspects required by e.g. the ECHA RAAF and other templates.  
The questions in Table 4 and overall analyses find commonalities with the main types of uncertainty and 
characteristics of the previously published schemes [6, 10, 12-15] summarised in Tables S1-S5 (of 
Supplementary Information) respectively. It is clear that the previous schemes take very different 
approaches to what types of uncertainty and characteristics may be addressed and how to do this, 
although there are overlaps in coverage of areas of uncertainties. The six schemes have been mapped, as 
completely as possible, onto the questions developed in this study and the results of this mapping are 
shown in Table 5. This shows the ECHA RAAF to be the most comprehensive, although it is noted that this 
assessment is from the questions derived from all possible RAAF scenarios (as in Table S4). The OECD 
Template for addressing uncertainties (see Table S5) is a brief set of questions but is intended to support 
the overall documentation process. The uncertainties identified and questions developed in this study 
(Table 4) have unified the assessment of uncertainty and provide a comprehensive and usable generic 
means to assess all relevant aspects of a read-across prediction. As such, responses to the questions in 
Table 4 provide a comprehensive means of assessing a read-across prediction that can be applied by a risk 
assessor or toxicologist that is favourable to ECHA’s RAAF whilst covering the same information. The 
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questions, and associated flowchart for implementation (Figure 2), allow for a decision on the suitability 
of a read-across for a particular purpose to be made by ensuring that assessor places the decision to be 
made at an appropriate level of uncertainty.  
 
INSERT FIGURE 2 HERE  
 
Whilst not an overall goal of the investigation, analysis of the case studies using the questions in Table 4 
allowed for a rating, or grading, of the responses. Specifically in the case studies assessed in this 
investigation, qualitative grading schemes (e.g., low, medium and high) were utilised as proposed by 
Schultz et al [15] following review of the practice at that time. Assignment of such a grading is inevitably 
subjective and the allocation of uncertainty (in this case low, moderate or high) can be undertaken with 
more or fewer classifications, or even a numerical scoring scheme, according to need, context and 
requirement. However, in this assessment the gradings were interpreted to provide regulatory relevance, 
e.g.,  an overall uncertainty of “low” has been stated [12, 13] to indicate that the overall the read-across 
prediction is equivalent to the information that would be provided from a standardised in vivo test (i.e., 
for these examples this implies OECD TG 408, Subchronic Oral Toxicity: 90-Day Study). This is in 
accordance with the requirements of legislation such as REACH in the EU. Likewise, assigning an overall 
uncertainty of “medium” means the read-across prediction is likely to be similar to doing a standardised 
in vivo test. An overall uncertainty of “high” means it is not possible to assess the uncertainty in relation 
to doing a standardised in vivo test.  
The assessment of uncertainties using the questions in Table 4 demonstrates the importance of 
understanding the context of the read-across and how the problem was formulated. The case studies 
analysed in this investigation required a high level of confidence, associated with low uncertainty, to be 
acceptable. For other regulatory contexts and decisions, a different level of uncertainty will be acceptable. 
Further work in this particular area is needed to determine the level of uncertainty, and how that can be 
determined, for acceptance of read-across different types of regulatory decisions and scenarios. In 
addition, as well as being applicable to the range of regulatory decisions, the questions are equally 
applicable to endpoints and effects other than repeated-dose toxicity. It is also important to consider that 
whilst in this investigation the uncertainties have been anchored on in vivo data, this need not be the case 
and relevant in vitro, molecular biology (omics) or other data may be appropriate. Thus, the questions in 
Table 4 are broadly applicable and adaptable to a whole variety of scenarios.  
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Table 4. Questions to address in assessing uncertainties of a read-across and summary of responses from the six case studies.  
Num
ber 
Uncertainty in Read-
Across  
Questions that Need to be Addressed Regarding 
Uncertainty 
Summary of the Level and Types of 
Uncertainties Identified in the Case Studies 
Following Analysis of the Questions (see 
Supplementary Information Tables S6-S11) 
1 The context of, and 
relevance to, the regulatory 
use of the read-across 
prediction as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across 
prediction clearly defined? 
 Is the acceptable level or degree of uncertainty for 
the stated purpose defined? 
 Is the stated acceptable level or degree of 
uncertainty appropriate for the stated regulatory 
purpose? 
Low uncertainty, all case studies related to risk 
assessment 
2 Type of category / group 
including the definition of 
the applicability domain. 
 Is the read-across approach (e.g., analogue or 
category) clearly reported? 
 Are the target and source chemicals clearly 
identified? 
 Is the applicability domain of the analogue or 
category defined? 
 Do target and source chemicals fit within the 
defined applicability domain? 
Low uncertainty, whilst varying between case 
studies, chemicals were clearly identified. 
Applicability domains were well defined (in 
terms of chemistry and properties); target and 
sources compounds fell within the stated 
domains. 
3 The premise or hypothesis 
of the read-across. 
 Is the hypothesis on which the read-across is based 
clearly stated and presented in sufficient detail to 
be assessed? 
Low uncertainty, all case studies had clearly 
stated hypotheses. 
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4 Mechanistic plausibility 
including completeness of 
the understanding of the 
MoA or AOP. 
 How clearly does the hypothesis state the chemical 
and biological mechanisms underpinning the toxic 
effect being read across? 
 Is there sufficient experimental information 
provided to support the proposed chemical and 
toxicological mechanisms? 
 How extensively does the experimental 
information provided support the mechanistic 
plausibility and / or the AOP or MoA on which the 
read-across is based? 
Low – medium uncertainty. All case studies 
were based around a mechanistic hypothesis. 
However levels of experimental evidence, and 
hence uncertainty varied. Only CS1 and CS3 had 
low uncertainty, other case studies had medium 
uncertainty due to the lack of supporting 
evidence.  
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, 
isomers, SMILES and molecular formula) reported 
for the derivatives used in the read-across? 
 Are the dissimilarities in chemical structure 
reported and are they toxicologically relevant?  
 Are the relevant molecular and physico-chemical 
properties (e.g., for molecular size, hydrophobicity, 
solubility, volatility, degradation etc.) reported for 
the derivatives used in the read-across? 
 Are the dissimilarities in molecular and physico-
chemical properties reported and are they 
toxicologically (or pharmacokinetically) relevant? 
Low uncertainty. All case studies reported 
target and source compounds accurately with 
extensive information on structure and 
properties. Dissimilarity in structures was well 
described and the differences accounted for.  
6 Toxicodynamic similarity.  Is there sufficient and consistent toxicodynamic 
information provided to establish similarity in the 
hazard of the derivatives used in the read-across? 
Low uncertainty. Within the context of 
mechanistic plausibility, all case studies 
reported toxicodynamic properties sufficiently 
well to establish similarity in hazard. 
21 
 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to 
establish toxicokinetic similarity for the derivatives 
used in the read-across? 
 Are any dissimilarities in ADME properties (and, as 
appropriate, metabolism / degradation) 
toxicologically relevant? 
Low to medium uncertainty. CS2, CS3 and CS5 
all had medium levels of uncertainty due to the 
lack of toxicokinetic / ADME data to 
demonstrate similarity between the target and 
source compounds.  
8 The quality of the apical 
endpoint data used to fill 
the data gap   
 Is the performance (e.g., reliability, accuracy, 
precision, repeatability and reproducibility) of the 
data read across reported clearly? 
 Has the quality of the data to be read across been 
assessed and are they sufficient to meet the 
purpose of the exercise i.e., complete and of 
sufficient quality? 
Low uncertainty. All cases studies were 
associated with high quality data.  
9 The consistency in the 
effects and severity of the 
apical in vivo hazard and 
their concordance with 
regards to the intermediate 
and apical effects and 
potency data. 
 Is the qualitative expression of the data reported 
and is it consistent among the source chemicals? 
 Is the potency of the hazard reported and is it 
consistent among the source chemicals? 
 What are the temporal relationships between 
relevant endpoints? 
 What are the dose-response relationships between 
relevant endpoints? 
Low to high uncertainty. There was generally 
low uncertainty with regard to effects and 
potency data. However, no case studies 
discussed the dose-response relationships. CS2 
and CS5 had medium uncertainty due to 
differences in length of the tests. CS4 and CS6 
showed differences in potency, effects and 
hazard and were assigned medium potency as a 
result. 
10 Strength or robustness of 
the supporting data sets. 
 How extensively are the relevant or key events 
either empirically measured and/or modelled by 
appropriate in silico, in chemico and in vitro data? 
Low uncertainty. All case studies were well 
supported by other data, including those from 
New Approach Methodologies (NAMs). 
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 Is the performance (e.g., reliability, accuracy, 
precision, repeatability and reproducibility) of the 
supporting methods adequately reported? 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information 
(e.g., structural alerts) between analogues or 
within the category? 
 How many and how large are the dissimilarities in 
the supporting information (i.e., data gaps)? 
Low uncertainty. All case studies showed a 
strong weight of evidence, combining multiple 
lines of evidence that supported the read-
across hypothesis. 
12 Documentation and written 
evidence provided 
 Is the read-across prediction adequately 
documented? 
 Does the evidence support the hypothesis that the 
uncertainty is acceptable for the stated purpose 
(as per Question 1)? 
Low uncertainty. All case studies were 
thoroughly documented in terms of 
argumentation and the presentation of data. 
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Table 5. Mapping of information relevant to identified uncertainties to existing read-across templates and schemes. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed 
Regarding Uncertainty 
Wu et al [10] 
Summarised 
in Table S1 
Blackburn and 
Stuard [12] 
Summarised 
in Table S2 
Schultz et al 
[13] 
Summarised 
in Table S3 
ECHA RAAF 
[15] 
Assessment 
Elements 
Summarised 
in Table S4 
(Draft) OECD 
Template for 
Reporting 
Uncertainty 
[6, 14] 
Summarised 
in Table S5 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
Is the regulatory purpose of the read-
across prediction clearly defined? 
No No Yes Yes No 
Is the acceptable level or degree of 
uncertainty for the stated purpose 
defined? 
No No Yes Yes No 
Is the stated acceptable level or degree of 
uncertainty appropriate for the stated 
regulatory purpose? 
No No Yes  Yes No 
2 Type of category / 
group including the 
definition of the 
applicability domain. 
Is the read-across approach (e.g., 
analogue or category) clearly reported? 
No Yes Yes Yes Yes 
Are the target and source chemicals 
clearly identified? 
Yes Yes Yes Yes Yes 
Is the applicability domain of the 
analogue or category defined? 
No No Yes Yes No 
Do target and source chemicals fit within 
the defined applicability domain? 
No No Yes Yes No 
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3 The premise or 
hypothesis of the read-
across. 
 Is the hypothesis on which the read-
across is based clearly stated and 
presented in sufficient detail to be 
assessed? 
No No Yes Yes Yes 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state 
the chemical and biological mechanisms 
underpinning the toxic effect being read 
across? 
No No Yes Yes Yes 
 Is there sufficient experimental 
information provided to support the 
proposed chemical and toxicological 
mechanisms? 
No No Yes Yes Yes 
 How extensively does the experimental 
information provided support the 
mechanistic plausibility and / or the 
AOP or MoA on which the read-across is 
based? 
No No Yes Yes Yes 
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D 
structure, isomers, SMILES and 
molecular formula) reported for the 
derivatives used in the read-across? 
Yes Yes Yes Yes Yes 
 Are the dissimilarities in chemical 
structure reported and are they 
toxicologically relevant?  
Yes Yes Yes Yes Yes 
 Are the relevant molecular and physico-
chemical properties (e.g., for molecular 
size, hydrophobicity, solubility, 
Yes Yes Yes Yes Yes 
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volatility, degradation etc.) reported for 
the derivatives used in the read-across? 
 Are the dissimilarities in molecular and 
physico-chemical properties reported 
and are they toxicologically (or 
pharmacokinetically) relevant? 
Yes Yes Yes Yes Yes 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent 
toxicodynamic information provided to 
establish similarity in the hazard of the 
derivatives used in the read-across? 
No No Yes Yes No 
7 Toxicokinetic similarity.  Is there sufficient ADME information 
provided to establish toxicokinetic 
similarity for the derivatives used in the 
read-across? 
No No Yes Yes Yes 
 Are any dissimilarities in ADME 
properties (and, as appropriate, 
metabolism / degradation) 
toxicologically relevant? 
No No Yes Yes Yes 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, 
accuracy, precision, repeatability and 
reproducibility) of the data read across 
reported clearly? 
No  Yes  Yes Yes Yes 
 Has the quality of the data to be read 
across been assessed and are they 
sufficient to meet the purpose of the 
exercise i.e. complete and of sufficient 
quality? 
No Yes Yes Yes Yes 
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9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data 
reported and is it consistent among the 
source chemicals? 
No Yes Yes Yes Yes 
 Is the potency of the hazard reported 
and is it consistent among the source 
chemicals? 
No Yes Yes Yes Yes 
 What are the temporal relationships 
between relevant endpoints? 
No Yes Yes Yes Yes 
 What are the dose-response 
relationships between relevant 
endpoints? 
No Yes Yes Yes Yes 
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key 
events either empirically measured 
and/or modelled by appropriate in 
silico, in chemico and in vitro data? 
No No Yes Yes Yes 
 Is the performance (e.g., reliability, 
accuracy, precision, repeatability and 
reproducibility) of the supporting 
methods adequately reported? 
No No Yes Yes Yes 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive 
information (e.g., structural alerts) 
between analogues or within the 
category? 
No Yes Yes Yes Yes 
 How many and how large are the 
dissimilarities in the supporting 
information (i.e., data gaps)? 
No  Yes Yes  Yes  Yes  
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12 Documentation and 
written evidence 
provided 
 Is the read-across prediction adequately 
documented? 
No No No No No 
 Does the evidence support the 
hypothesis that the uncertainty is 
acceptable for the stated purpose (as 
per Question 1)? 
No No Yes Yes No 
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Conclusions 
 
Read-across has become an essential tool to fill toxicity data gaps, in particular supporting a number of 
regulatory applications including, but not limited to, (quantitative) risk assessment, classification and 
labelling as well as screening and prioritisation. The acceptance of a read-across prediction for regulatory 
purposes is a complex and occasionally ambiguous process. However, it is acknowledged that for a read-
across to be accepted for a specific regulatory purpose uncertainties must be identified and be 
appropriate. As such, uncertainties for read-across must be established and ideally quantified. To this end, 
a number of schemes have been published ranging from assessment of individual aspects of describing 
the read-across [10, 12] through to more comprehensive assessments with a particular focus on enabling 
regulatory acceptance [6, 13, 15]. This study attempted to harmonise all the current knowledge of 
uncertainties by focussing on the uncertainties that could be identified in case studies for one of the most 
challenging toxicological endpoints (repeated dose toxicity).  
 
Based on a review of existing knowledge and how it was applied to the information presented in six case 
studies, a variety of uncertainties were identified that potentially impact on the regulatory acceptance of 
read-across predictions. Four main sources of uncertainty were identified including that associated with 
the regulatory use of the read-across prediction; the quality and relevance of the apical endpoint data 
being read across; the read-across argumentation; and the similarity justification. A total of twelve types 
of uncertainty were defined that cross over and describe these four sources fully. In order to enable use 
of this knowledge and to facilitate determination and evaluation of uncertainties, a series of 30 questions 
was formulated that guide the read-across developer and assessor through the assessment of all relevant 
uncertainties. The six case studies were assessed in terms of the questions developed demonstrating that 
areas such as mechanistic plausibility, the quality of the data being read across and inclusion of 
information on toxicokinetics were important uncertainties to reduce.  The questions cover and extend 
all the uncertainties documented in existing schemes and place them into a rapidly applied generic 
framework. This findings of this study, whilst focussed on read-across for repeated dose toxicity, have the 
possibility to be applied to other endpoints, effectsand read-across scenarios.  
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Figure Titles.  
 
 
Figure 1.   Schematic depiction of the interrelationships between the sources and types on uncertainty in 
a read-across. Solid boxes with Roman numbers (I – IV) represent the main sources as identified in Table 
2. Arabic numbers (1 – 12) represent the types of uncertainties as described in Table 3.  
 
Figure 2. Workflow for applying the questions related to uncertainty in Table 4. The numbers in 
parenthesis relate to the questions in Table 4. It is intended that Question 1 should inform Question 12, 
i.e. the context and problem formulation will inform the level of uncertainty acceptable for the purpose 
of the read-across and whether that is achieved.  
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Table S1. Criteria related to uncertainty of a read-across based on the discussion, decision tree and 
templates described by Wu et al. [10]*  
 
 
 
* S. Wu, K. Blackburn, J. Amburgey, J. Jaworska, T. Federle, A framework for using structural, reactivity, 
metabolic and physicochemical similarity to evaluate the suitability of analogs for SAR-based toxicological 
assessments, Regul. Toxicol. Pharmacol. 56 (2010) 67-81. 
  
Evaluation Criteria Features Evaluated 
Structure and reactivity Commonality of structural alerts 
 Commonality of key functional groups 
 Commonality in position of double bonds 
 Effects of additional functional groups 
Physicochemical properties Commonality of properties including molecular weight, distribution 
coefficient (log D) (combining the ionisation constant (pKa) and 
partition coefficient (log P)) and aqueous solubility 
Metabolism Commonality of metabolic pathways 
 Potential for the analogue to metabolise to the target or a highly 
related compound as well as that for the target to metabolise to the 
analogue 
 Potential for the metabolism of the analogue and the target to 
converge on a common stable metabolite or reactive metabolite with 
the same mode of action  
 Potential for the metabolism of the analogue and the target to diverge 
on different bioactivation pathway to alter the toxicological profile of 
the analogue or target.  
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Table S2. Criteria related to uncertainty of a read-across based on the templates described by Blackburn 
and Stuard [12]*  
 
 
Analogue Data Set Characteristics f 
Number of analogues contributing data 
Robustness of analogue data set 
Concordance of effect(s) 
Concordance of potency 
Severity of critical effects 
 
* K. Blackburn, S.B. Stuard, A framework to facilitate consistent characterization of read across 
uncertainty, Regul. Toxicol. Pharmacol. 68 (2014) 353-362 
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Table S3. Criteria related to uncertainty of a read-across based on the templates described by Schultz et 
al [13]*  
 
Part 1: Data Uncertainty and Weight-of-Evidence Associated with the Fundamentals of Chemical, 
Transformation/Toxicokinetic and Toxicological Similarity. 
Similarity Parameter  
Substance identification, structure and chemical classifications 
Physio-chemical and molecular properties 
Substituents, functional groups and extended structural fragments 
Transformation/toxicokinetics and metabolic similarity 
Potential metabolic products 
Toxicophores /mechanistic lerts 
Mechanistic plausibility and AOP-related events 
Other relevant, in vivo, in vitro and ex vivo endpoints 
 
Part 2: Template for Assessing Uncertainty Associated with Mechanistic Relevance and Completeness of 
the Read-Across. 
Uncertaintye 
The problem and premise of the read-across 
Number of analogues in the source set 
Quality of the in vivo apical endpoint data read across 
Severity of the apical in vivo hazard 
Robustness of analogue data set 
Concordance with regard to the intermediate and apical effects and potency data 
Weight of Evidence 
 
* T.W. Schultz, P. Amcoff, E. Berggren, F. Gautier, M, Klaric, D.J. Knight, C. Mahony, M. Schwarz, A. White, 
M.T.D. Cronin, A strategy for structuring and reporting a read-across prediction of toxicity, Regul. Toxicol. 
Pharmacol. 72 (2015) 586-601. 
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Table S4. Criteria related to the confidence (which are analogous to the uncertainties in this investigation) 
that may be assigned to a read-across based on ECHA’s RAAF Assessment Elements [15]*  
 
Assessment  
Element (AE) 
Number(s) 
Assessment Element 
  
Scientific Assessment of Human Health Effects 
  
Analogue Approach, Scenarios 1-2 
  
AE A.1  Identity and characterisation of the source substance 
AE A.2  Link of structural similarities and differences with the proposed prediction 
AE A.3  Reliability and adequacy of the source study 
AE A.4  Bias that influences the prediction 
AE 1.1  Formation of common (identical) compound(s) 
AE 1.2  The biological targets for the common compound(s) 
AE 1.3  Exposure of the biological target(s) to the common compound(s) 
AE 1.4  The impact of parent compounds 
AE 1.5  Formation and impact of non-common compounds 
AE 2.1  Compounds the test organism is exposed to 
AE 2.2  Common underlying mechanism, qualitative aspects 
AE 2.3  Common underlying mechanism, quantitative aspects 
AE 2.4  Exposure to other compounds than to those linked to the prediction 
AE 2.5  Occurrence of other effects than covered by the hypothesis and justification 
  
Category Approach, Scenarios 3-6 
  
AE C.1  Substance characterisation 
AE C.2  Structural similarity and differences within the category 
AE C.3  
 
Link of structural similarities and structural differences with the proposed 
regular pattern 
AE C.4  Consistency of effects in the data matrix 
AE C.5  Reliability and adequacy of the source study(ies) 
AE C.6  Bias that influences the prediction 
AE 3.1 AE 5.1  
 
Formation of common (identical) compound(s) 
AE 3.2 AE 5.2  The biological target(s) for the common compound(s) 
AE 3.3 AE 5.3  Exposure of the biological target(s) to the common compound(s) 
AE 3.4 AE 5.4  The impact of parent compounds 
AE 3.5 AE 5.5  Formation and impact of non-common compounds 
AE 4.1 AE 6.1  Compounds the test organism is exposed to 
AE 4.2 AE 6.2  Common underlying mechanism, qualitative aspects 
AE 4.3 AE 6.3  Common underlying mechanism, quantitative aspects 
AE 4.4 AE 6.4  Exposure to other compounds than those linked to the prediction 
AE 4.5 AE 6.5  Occurrence of other effects than covered by the hypothesis and 
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justification 
  
Scientific Assessment of Environmental Fate and Effects 
  
Analogue Approach, Scenarios 1-2 
  
AE A.1  Characterisation of source and target substances 
AE A.2  Link of structural similarities and structural differences with the proposed 
prediction (presence of hypothesis) 
AE A.3  Impact of impurities on the prediction 
AE A.4  Consistency of properties in the data matrix 
AE A.5  Reliability and adequacy of the source data AE 
AE A.6  Bias that influences the prediction 
AE 1.1  Formation of common (identical) and non-common compounds 
AE1.2  Degradation of non-common compounds 
AE 1.3  Bioaccumulation potential of non-common compounds 
AE 1.4  Impact of non-common compound 
AE 2.1  Degradation 
AE 2.2  Bioaccumulation potential 
AE 2.3  Common underlying mechanism, qualitative aspects 
AE 2.4  Common underlying mechanism, quantitative aspect 
  
Category Approach, Scenarios 3-6 
  
AE C.1  Characterisation of source and target substances 
AE C.2  Structural similarity and dissimilarity within the category (category description) 
AE C.3  Link of structural similarities and structural differences with the proposed 
regular pattern (presence of hypothesis) 
AE C.4  Impact of impurities on the prediction 
AE C.5  Consistency of properties in the data matrix 
AE C.6  Reliability and adequacy of the source data 
AE C.7  Bias that influences the prediction 
AE 3.1 AE 5.1  Formation of common (identical) and non-common compound(s) 
AE 3.2 AE 5.2  Degradation of non-common compounds 
AE 3.3 AE 5.3  Bioaccumulation potential of non-common compounds 
AE 3.4 AE 5.4  Impact of non-common compounds 
AE 4.1 AE 6.1  Degradation 
AE 4.2 AE 6.2  Bioaccumulation potential 
AE 4.3 AE 6.3  Common underlying mechanism, qualitative aspects 
AE 4.4 AE 6.4  Common underlying mechanism, quantitative aspects 
 
* European Chemicals Agency (ECHA) Read-Across Assessment Framework (RAAF). European Chemicals 
Agency, Helskinki, 2017.  
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Table S5. Criteria related to uncertainty of a read-across extracted from the OECD [6, 14]* template for of 
reporting uncertainty. 
 
Uncertainty 
Hypothesis used for the read across 
Structural similarity 
Similarity of physico-chemical properties 
Similarity of toxicokinetics data 
Similarity of other supportive data (e.g. data related to key event) 
Number of analogues used for the read across 
Quality of the endpoint data used for the read across 
Similarity of the endpoint data (among source chemicals) 
Concordance and weight of evidence of all data used for justifying the 
hypothesis 
Overall uncertainty of the read across 
 
* Organisation for Economic Cooperation and Development (OECD), Case Study on the Use of an 
Integrated Approach to Testing and Assessment for Hepatotoxicity of Allyl Esters, No. 253, Series on 
Testing & Assessment. ENV/JM/MONO(2016)51, OECD, Paris, 2016. 
Organisation for Economic Cooperation and Development (OECD), Report on Considerations from Case 
Studies on Integrated Approaches for Testing and Assessment (IATA), Third Review Cycle (2017), Case 
Studies on Grouping Methods as a Part of IATA, No. XXX, Series on Testing & Assessment. 
ENV/JM/MONO(2018)XX, OECD, Paris. In press, 2018. 
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Table S6. Uncertainties relating to Case Study 1 for n-alkanols (OECD [17]*) – for illustrative purposes only. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly defined? Yes Low  Section 1 (page 13) 
 Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
Yes Low  Section 1.1 (page 13) 
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
Yes  Low Section 1.1 (page 13) 
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low Section 1.2 (page 13); 
Section 2 (page 14) 
 Are the target and source chemicals clearly identified? Yes Low Table 3 (page 13) 
 Is the applicability domain of the analogue or category defined? Yes Low Section 2.2 (page 15) 
 Do target and source chemicals fit within the defined applicability 
domain? 
Yes Low Section 2.2 (page 15) 
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and presented 
in sufficient detail to be assessed? 
Yes Low Section 2 (page 14) 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Low Section 3 (pages 16-17); 
Table 5 (pages 21-22) 
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Low Section 3 (pages 16-17); 
Table 5 (pages 21-22) 
 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA is 
based? 
Very 
extensively 
stated 
Low Section 3 (pages 16-17); 
Table 5 (pages 21-22) 
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5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low Table 3 (page 13); Table 4 
(pages 19-20) 
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, 
relevant 
only to 
toxicokineti
cs 
Low Table 4 (pages 19-20) 
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low Table 4 (pages 19-20) 
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) relevant? 
Yes, 
relevant 
only to 
toxicokineti
cs 
Low Table 4 (pages 19-20) 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided to 
establish similarity in the hazard of the derivatives used in the RA? 
Yes Low Section 3 (pages 15-18); 
Table 5 (pages 21-22) 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish toxicokinetic 
similarity for the derivatives used in the RA? 
Yes Low Section 3 (pages 15-18); 
Table 4 (pages 20-21) 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Low Section 3 (pages 15-18); 
Table 4 (pages 20-21) 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 Has the quality of the data to be read across been assessed and are they 
sufficient to meet the purpose of the exercise i.e. complete and of 
sufficient quality? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
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9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 What are the temporal relationships between relevant endpoints? All 90 day Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 What are the dose-response relationships between relevant endpoints? Not 
reported 
High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level 
of 
dissimilarit
y 
Low Introduction (pages 8-12); 
Table 5 (pages 21-22) 
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low Complete document 
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
Yes Low Section 5 (pages 22-23) 
 
45 
 
* Organisation for Economic Cooperation and Development (OECD), Organisation for Economic Cooperation and Development (OECD), Case 
Study on the Use of Integrated Approaches for Testing and Assessment of 90-Day Rat Oral Repeated-Dose Toxicity for Selected n-Alkanols: Read-
Across, No. 273, Series on Testing & Assessment. ENV/JM/MONO(2017)25, OECD, Paris, 2017. 
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Table S7. Uncertainties relating to Case Study 2 for 2-alkyl-1-alkanols (OECD [18]*) – for illustrative purposes only. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly 
defined? 
Yes Low  Section 1 (page 12) 
 Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
Yes Low  Section 1.1 (page 12) 
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
Yes Low  Section 1.1 (page 12) 
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low Section 1.2 (page 12); 
Section 2 (pages 13-14) 
 Are the target and source chemicals clearly identified? Yes Low Table 3 (page 12) 
 Is the applicability domain of the analogue or category defined? Yes Low  Section 2.2 (page 15) 
 Do target and source chemicals fit within the defined applicability 
domain? 
Yes Low  Section 2.2 (page 15) 
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and 
presented in sufficient detail to be assessed? 
Yes Low Section 2 (page 13-14) 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Medium Section 3 (pages 15-21); 
Table 5 (pages 25-26) 
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Medium Section 3 (pages 15-21); 
Table 5 (pages 25-26) 
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 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA 
is based? 
Very 
extensively 
stated 
Medium Section 3 (pages 15-21); 
Table 5 (pages 25-26) 
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low Table 3 (page 12); Table 4 
(pages 23-24) 
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, relevant 
only to 
toxicokinetics 
Low Table 4 (pages 23-24) 
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low Table 4 (pages 23-24) 
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) 
relevant? 
Yes, relevant 
only to 
toxicokinetics 
Low Table 4 (pages 23-24) 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided 
to establish similarity in the hazard of the derivatives used in the RA? 
Yes Low Section 3 (pages 15-21); 
Table 5 (pages 25-26) 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish 
toxicokinetic similarity for the derivatives used in the RA? 
Yes Medium Section 3 (pages 15-18); 
Table 4 (pages 23-24) 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Medium Section 3 (pages 15-18); 
Table 4 (pages 23-24) 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 Has the quality of the data to be read across been assessed and are 
they sufficient to meet the purpose of the exercise i.e. complete and 
of sufficient quality? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
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9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 What are the temporal relationships between relevant endpoints? All 90 day Low to 
Medium 
Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 What are the dose-response relationships between relevant 
endpoints? 
Not reported High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level of 
dissimilarity 
Low Introduction (pages 9-11); 
Table 5 (pages 25-26) 
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low Complete document 
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
Yes Low  Section 5 (page 26) 
 
*Organisation for Economic Cooperation and Development (OECD), Case Study on the Use of Integrated Approaches for Testing and Assessment 
of 90-Day Rat Oral Repeated-Dose Toxicity for Selected 2-Alkyl-1-alkanols: Read-Across, No. 274, Series on Testing & Assessment. 
ENV/JM/MONO(2017)26, OECD, Paris, 2017. 
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Table S8. Uncertainties relating to Case Study 3 for aryl alcohol alkyl carboxylic esters (OECD [19]*) – for illustrative purposes only. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly 
defined? 
Yes Low  *NB Examples / page 
numbers not finalised as 
document is under review 
 Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
Yes Low   
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
   
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low  
 Are the target and source chemicals clearly identified? Yes Low  
 Is the applicability domain of the analogue or category defined?    
 Do target and source chemicals fit within the defined applicability 
domain? 
   
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and 
presented in sufficient detail to be assessed? 
Yes Low  
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Low  
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Low  
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 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA 
is based? 
Very 
extensively 
stated 
Low  
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low  
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, relevant 
only to 
toxicokinetics 
Low  
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low  
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) 
relevant? 
Yes, relevant 
only to 
toxicokinetics 
Low  
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided 
to establish similarity in the hazard of the derivatives used in the RA? 
Yes Low  
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish 
toxicokinetic similarity for the derivatives used in the RA? 
Yes Low to 
Medium 
 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Low to 
Medium 
 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low  
 Has the quality of the data to be read across been assessed and are 
they sufficient to meet the purpose of the exercise i.e. complete and 
of sufficient quality? 
Yes Low  
51 
 
9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low  
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Low  
 What are the temporal relationships between relevant endpoints? All 90 day Low to 
Medium 
 
 What are the dose-response relationships between relevant 
endpoints? 
Not reported High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low  
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low  
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low  
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level of 
dissimilarity 
Low  
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low  
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
   
 
* Organisation for Economic Cooperation and Development (OECD), A Case Study on the Use of Integrated Approaches for Testing and 
Assessment for Sub-Chronic Repeated-Dose Toxicity of Simple Aryl Alcohol Alkyl Carboxylic Esters: Read-Across, No. XXX, Series on Testing & 
Assessment. ENV/JM/MONO(2018)XX, OECD, Paris. In press, 2018. 
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Table S9. Uncertainties relating to Case Study 4 for short-chain mono-alkylphenols (Mellor et al, [21]*) – for illustrative purposes only. 
 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly 
defined? 
Yes Low  Introduction (pages 1-2) 
Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
No High  
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
No High  
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low Introduction (pages 1-2) 
and Hypothesis (page 4) 
 Are the target and source chemicals clearly identified? Yes Low Table 1 (page 4) 
 Is the applicability domain of the analogue or category defined? Yes Low Results (page 4) 
 Do target and source chemicals fit within the defined applicability 
domain? 
Yes Low Results (page 4) 
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and 
presented in sufficient detail to be assessed? 
Yes Low Introduction (pages 1-2) 
and Hypothesis (page 4) 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Low-to-
Medium 
Results (pages 4-9); Table 
4 (pages 8) 
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Low-to-
Medium 
Results (pages 4-9); Table 
4 (pages 8) 
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 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA 
is based? 
Very 
extensively 
stated 
Low-to-
Medium 
Results (pages 4-9); Table 
4 (pages 8) 
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low Supplementary 
Information: Table 1 
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, relevant 
only to 
toxicokinetics 
Low Results (page 4) 
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low ; Supplementary 
Information Table 2 
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) 
relevant? 
Yes, relevant 
only to 
toxicokinetics 
Low Results (pages 4-9); Table 
4 (pages 8) 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided 
to establish similarity in the hazard of the derivatives used in the RA? 
Yes Low Results (pages 4-9); Table 
4 (pages 8) 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish 
toxicokinetic similarity for the derivatives used in the RA? 
Yes Low Results (pages 4-9); Table 
4 (pages 8) 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Low Results (pages 4-9); Table 
4 (pages 8) 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low Results (pages 4-9); Table 
5 (pages 9) 
 Has the quality of the data to be read across been assessed and are 
they sufficient to meet the purpose of the exercise i.e. complete and 
of sufficient quality? 
Yes Low Results (pages 4-9); Table 
5 (pages 9) 
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9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low Results (pages 4-9); Table 
5 (pages 9) 
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Medium Results (pages 4-9); Table 
5 (pages 9) 
 What are the temporal relationships between relevant endpoints? All 90 day Low  Results (pages 4-9); Table 
5 (pages 9) 
 What are the dose-response relationships between relevant 
endpoints? 
Not reported High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low Results (pages 4-9); Table 
5 (pages 9); 
Supplementary 
Information  
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low Results (pages 4-9); Table 
5 (pages 9) 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low Results (pages 4-9); Table 
5 (pages 9) 
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level of 
dissimilarity 
Low Results (pages 4-9); Table 
5 (pages 9); 
Supplementary 
Information  
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low Complete document 
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
No High  
 
55 
 
* C.L. Mellor, T.W. Schultz, K.R. Przybylak, A.-N. Richarz, M.T.D Cronin, Read-across for rat oral gavage repeated-dose toxicity for short-chain 
mono-alkylphenols: A case study. Comput. Toxicol 2 (2017) 1-11.  
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Table S10. Uncertainties relating to Case Study 5 for allyl esters (OECD [14]*) – for illustrative purposes only. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly 
defined? 
Yes Low  Section 1 (page 9) 
 Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
No High  
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
No High  
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low Section 2 (pages 9-12) 
 Are the target and source chemicals clearly identified? Yes Low Table 1 (page 12-13) 
 Is the applicability domain of the analogue or category defined? Yes Low Section 4.3 (page 15) 
 Do target and source chemicals fit within the defined applicability 
domain? 
Yes Low Section 4.3 (page 15) 
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and 
presented in sufficient detail to be assessed? 
Yes Low Section 2 (pages 9-12) 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Medium Section 4 (pages 13-15); 
Table 3 (pages 19-20) 
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Medium Section 4 (pages 13-15); 
Table 3 (pages 19-20) 
 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA 
is based? 
Very 
extensively 
stated 
Medium Section 4 (pages 13-15); 
Table 3 (pages 19-20) 
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5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low Table 1 (page 12-13) 
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, relevant 
to 
toxicokinetics 
and 
mechanisms 
dependent 
on sub-
category 
Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) 
relevant? 
Yes, relevant 
only to 
toxicokinetics 
Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided 
to establish similarity in the hazard of the derivatives used in the RA? 
Yes Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish 
toxicokinetic similarity for the derivatives used in the RA? 
Yes Medium Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Medium Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
8  Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low Section 2 (pages 9-12); 
Annex 1 
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The quality of the apical 
endpoint data used to 
fill the data gap   
 Has the quality of the data to be read across been assessed and are 
they sufficient to meet the purpose of the exercise i.e. complete and 
of sufficient quality? 
Yes Low Section 2 (pages 9-12); 
Annex 1 
9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low Section 4.3 (pages 14-15)) 
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Low Section 4.3 (pages 14-15)) 
 What are the temporal relationships between relevant endpoints? All 90 day Low to 
Medium 
Section 4.3 (pages 14-15)) 
 What are the dose-response relationships between relevant 
endpoints? 
Not reported High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low Table 1 (page 12-13); 
Section 4 (pages 13-15); 
Section 5 (pages 15 -16) 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low Section 5 (pages 15 -16) 
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level of 
dissimilarity 
Low Section 5 (pages 15 -16) 
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low Complete document 
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
No High  
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Table S11. Uncertainties relating to Case Study 6 for -olefinic alcohols (Przybylak et al, [20]*) – for illustrative purposes only. 
Number Uncertainty in Read-
Across 
Questions that Need to be Addressed Regarding Uncertainty Brief 
Response 
Associated 
Uncertainty 
Source of Evidence or 
Supporting Information 
1 The context of, and 
relevance to, the 
regulatory use of the 
read-across prediction 
as defined by 
appropriate problem 
formulation. 
 Is the regulatory purpose of the read-across prediction clearly 
defined? 
Yes Low  Introduction (pages 22-
23) 
 Is the acceptable level or degree of uncertainty for the stated purpose 
defined? 
Yes Low  Introduction (page 23) 
 Is the stated acceptable level or degree of uncertainty appropriate for 
the stated regulatory purpose? 
Yes Low  Introduction (page 23) 
2 Type of category / 
group including the 
definition of the 
applicability domain. 
 Is the read-across approach (e.g., analogue or category) clearly 
reported? 
Yes Low Introduction (pages 22-
23) and Hypothesis 
(pages 23-24) 
 Are the target and source chemicals clearly identified? Yes Low Table 1 (page 24) 
 Is the applicability domain of the analogue or category defined? Yes Low Results (page 25) 
 Do target and source chemicals fit within the defined applicability 
domain? 
Yes Low Results (page 25) 
3 The premise or 
hypothesis of the RA. 
 Is the hypothesis on which the RA is based clearly stated and 
presented in sufficient detail to be assessed? 
Yes Low Introduction (pages 22-
23) and Hypothesis (page 
23-24) 
4 Mechanistic plausibility 
including completeness 
of the understanding of 
the MoA or AOP. 
 How clearly does the hypothesis state the chemical and biological 
mechanisms underpinning the toxic effect being read across? 
Very clearly 
stated 
Medium Results (pages 24-31); 
Table 4 (page 29) 
 Is there sufficient experimental information provided to support the 
proposed chemical and toxicological mechanisms? 
Yes Medium Results (pages 24-31); 
Table 4 (page 29) 
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 How extensively does the experimental information provided support 
the mechanistic plausibility and / or the AOP or MoA on which the RA 
is based? 
Very 
extensively 
stated 
Medium Results (pages 24-31); 
Table 4 (page 29) 
5 Similarity in chemistry.  Are the chemical structures (i.e., 2D structure, isomers, SMILES and 
molecular formula) reported for the derivatives used in the RA? 
Yes Low Table 1 (page 24); 
Supplementary 
Information: Table 1 
 Are the dissimilarities in chemical structure reported and are they 
toxicologically relevant?  
Yes, relevant 
only to 
toxicokinetics 
Low Results (pages 24-31) 
 Are the relevant molecular and physico-chemical properties (e.g., for 
molecular size, hydrophobicity, solubility, volatility, degradation etc.) 
reported for the derivatives used in the RA? 
Yes Low Supplementary 
Information Table 2 
 Are the dissimilarities in molecular and physico-chemical properties 
reported and are they toxicologically (or pharmacokinetically) 
relevant? 
Yes, relevant 
only to 
toxicokinetics 
Low Results (pages 24-31); 
Table 4 (page 29) 
6 Toxicodynamic 
similarity. 
 Is there sufficient and consistent toxicodynamic information provided 
to establish similarity in the hazard of the derivatives used in the RA? 
Yes Low Results (pages 24-31); 
Table 4 (page 29) 
7 Toxicokinetic similarity.  Is there sufficient ADME information provided to establish 
toxicokinetic similarity for the derivatives used in the RA? 
Yes Low Results (pages 24-31); 
Table 4 (page 29) 
 Are any dissimilarities in ADME properties (and, as appropriate, 
metabolism / degradation) toxicologically relevant? 
No – or as 
stated 
Low Results (pages 24-31); 
Table 4 (page 29) 
8 The quality of the apical 
endpoint data used to 
fill the data gap   
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the data read across reported clearly? 
Yes Low Results (pages 24-31); 
Table 5 (page 30) 
 Has the quality of the data to be read across been assessed and are 
they sufficient to meet the purpose of the exercise i.e. complete and 
of sufficient quality? 
Yes Low Results (pages 24-31); 
Table 5 (page 30) 
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9 The consistency in the 
effects and severity of 
the apical in vivo hazard 
and their concordance 
with regards to the 
intermediate and apical 
effects and potency 
data. 
 Is the qualitative expression of the data reported and is it consistent 
among the source chemicals? 
Yes Low Results (pages 24-31); 
Table 5 (page 30) 
 Is the potency of the hazard reported and is it consistent among the 
source chemicals? 
Yes Medium Results (pages 24-31); 
Table 5 (page 30) 
 What are the temporal relationships between relevant endpoints? All 90 day Low  Results (pages 24-31); 
Table 5 (page 30) 
 What are the dose-response relationships between relevant 
endpoints? 
Not reported High  
10 Strength or robustness 
of the supporting data 
sets. 
 How extensively are the relevant or key events either empirically 
measured and/or modelled by appropriate in silico, in chemico and in 
vitro data? 
Well 
reported 
Low Results (pages 24-31); 
Table 5 (page 30) 
Supplementary 
Information  
 Is the performance (e.g., reliability, accuracy, precision, repeatability 
and reproducibility) of the supporting methods adequately reported? 
Yes Low Results (pages 24-31); 
Table 5 (page 30) 
11 The Weight-of-Evidence 
(WoE) supporting the 
prediction. 
 Is there consistency in the supportive information (e.g., structural 
alerts) between analogues or within the category? 
Yes Low Results (pages 24-31); 
Table 5 (page 30) 
 How many and how large are the dissimilarities in the supporting 
information (i.e., data gaps)? 
Small level of 
dissimilarity 
Low Results (pages 24-31); 
Table 5 (page 30) 
Supplementary 
Information  
12 Documentation and 
written evidence 
provided 
 Is the RA prediction adequately documented? Yes Low Complete document 
 Does the evidence support the hypothesis that the uncertainty is 
acceptable for the stated purpose (as per Question 1)? 
Yes  Low  Conclusions (page 25) 
 
* K.R. Przybylak, T.W. Schultz, A.-N. Richarz, C.L. Mellor, S.E. Escher, M.T.D Cronin, Read-across of 90-day rat oral repeated-dose toxicity: A case 
study for selected β-olefinic alcohols. Comput. Toxicol. 1 (2017) 22-32.
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